Corporate News

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in advanced Magnetic Resonance Imaging ("MRI") of lung function, confirms that it will be announcing its full year results for the year ended 30 December 2024 on Thursday, 8 May 2025.

Christopher von Jako, PhD, Chief Executive Officer, and Charles Osborne, Chief Financial Officer, will be hosting a live online presentation relating to the results via the Investor Meet Company platform on Thursday, 8 May 2025 at 15.00 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your IMC dashboard up until 9.00 BST the day before the meeting or in real time during the presentation.

Investors can sign up to Investor Meet Company for free and add to meet Polarean Imaging Plc here. Investors who already follow Polarean on the Investor Meet Company platform will automatically be invited.

Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation will be available on the Investor Meet Company platform afterwards.

 

Enquiries: 

Polarean Imaging Plc			www.polarean.com / www.polarean-ir.com
Christopher von Jako, PhD, Chief Executive Officer			Via Walbrook PR
Charles Osborne, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)				+44 (0)20 7710 7600
Nicholas Moore / Nick Harland / Brough Ransom / Ben Good
Walbrook PR	Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Paul McManus		Mob: +44 (0)7876 741 001 / +44 (0) 7980 541 893

 

About Polarean

Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform. For the latest news and information about Polarean, please visit www.polarean.com.